Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

157.14
+0.57000.36%
Volume:180.46K
Turnover:28.46M
Market Cap:16.03B
PE:23.03
High:159.67
Open:157.96
Low:156.54
Close:156.57
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.11
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.34
PE(LYR):33.65

Loading ...

Neurocrine Price Target Cut to $182.00/Share from $196.00 by Morgan Stanley

Dow Jones
·
Aug 13

Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Aquestive Therapeutics (AQST)

TIPRANKS
·
Aug 13

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

MT Newswires Live
·
Aug 13

Neurocrine Biosciences, Inc. : Deutsche Bank Cuts Target Price to $165 from $190

THOMSON REUTERS
·
Aug 13

Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Global Markets Steady as AI Optimism Returns, Focus Shifts to US Inflation Data

Deep News
·
Aug 12

Neurocrine Biosciences Announces Publication of Kinect-Pro™ Findings Demonstrating Ingrezza® (Valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

THOMSON REUTERS
·
Aug 12

Prader-Willi Groups Cite Deaths Tied to Neurocrine's Genetic Disorder Drug, Shares Fall

Reuters
·
Aug 12

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

GlobeNewswire
·
Aug 10

Sector Update: Healthcare Stocks Rise Late Afternoon

MT Newswires Live
·
Aug 08

Neurocrine Launches Phase 1 Trial of NBIP-1968 Triple-Agonist Obesity Drug

Reuters
·
Aug 07

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Nbip-'1968, a Glp-1/Gip/Glucagon Receptor Triple Agonist

THOMSON REUTERS
·
Aug 07

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

TIPRANKS
·
Aug 07

Nxera Pharma Swings to FY26 H1 Net Profit of JPY 1.59 Billion; Revenue Rises to JPY 18.91 Billion

Reuters
·
Aug 07

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 07

Voyager Q2 FY26 Net Loss Narrows to $24.47 Million; Revenue Falls to $3.17 Million

Reuters
·
Aug 07

Neurocrine is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 03

Neurocrine Amends 8-K to Update Pro Forma Financials for Soleno Acquisition

Reuters
·
Aug 01

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

TIPRANKS
·
Aug 01